Next Article in Journal
Membrane Deformation and Its Effects on Flow and Mass Transfer in the Electromembrane Processes
Next Article in Special Issue
New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise
Previous Article in Journal
Quorum Sensing as Antivirulence Target in Cystic Fibrosis Pathogens
Previous Article in Special Issue
Antigen Targets for the Development of Immunotherapies in Leukemia
Review

Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options

1
Hematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, and University of Milan, 20122 Milan, Italy
2
Division of Pathology, Department of Pathophysiology and Transplantation, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, and University of Milan, 20122 Milan, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(8), 1839; https://doi.org/10.3390/ijms20081839
Received: 8 March 2019 / Revised: 9 April 2019 / Accepted: 11 April 2019 / Published: 13 April 2019
(This article belongs to the Special Issue Advances in Molecular Biology and Targeted Therapy of Leukemias)
Myeloproliferative neoplasms represent a heterogenous group of disorders of the hematopoietic stem cell, with an intrinsic risk of evolution into acute myeloid leukemia. The frequency of leukemic evolution varies according to myeloproliferative neoplasms subtype. It is highest in primary myelofibrosis, where it is estimated to be approximately 10–20% at 10 years, following by polycythemia vera, with a risk of 2.3% at 10 years and 7.9% at 20 years. In essential thrombocythemia, however, transformation to acute myeloid leukemia is considered relatively uncommon. Different factors are associated with leukemic evolution in myeloproliferative neoplasms, but generally include advanced age, leukocytosis, exposure to myelosuppressive therapy, cytogenetic abnormalities, as well as increased number of mutations in genes associated with myeloid neoplasms. The prognosis of these patients is dismal, with a medium overall survival ranging from 2.6–7.0 months. Currently, there is no standard of care for managing the blast phase of these diseases, and no treatment to date has consistently led to prolonged survival and/or hematological remission apart from an allogeneic stem cell transplant. Nevertheless, new targeted agents are currently under development. In this review, we present the current evidence regarding risk factors, molecular characterization, and treatment options for this critical subset of myeloproliferative neoplasms patients. View Full-Text
Keywords: myeloproliferative neoplasms; blast phase; secondary acute leukemia; mutations; targeted therapies myeloproliferative neoplasms; blast phase; secondary acute leukemia; mutations; targeted therapies
Show Figures

Figure 1

MDPI and ACS Style

Iurlo, A.; Cattaneo, D.; Gianelli, U. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options. Int. J. Mol. Sci. 2019, 20, 1839. https://doi.org/10.3390/ijms20081839

AMA Style

Iurlo A, Cattaneo D, Gianelli U. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options. International Journal of Molecular Sciences. 2019; 20(8):1839. https://doi.org/10.3390/ijms20081839

Chicago/Turabian Style

Iurlo, Alessandra, Daniele Cattaneo, and Umberto Gianelli. 2019. "Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options" International Journal of Molecular Sciences 20, no. 8: 1839. https://doi.org/10.3390/ijms20081839

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop